NCT03682380View on ClinicalTrials.gov

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

August 23, 2019

Study Completion Date

August 23, 2019

Conditions
Healthy
Interventions
DRUG

Seltorexant High Dose

In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.

DRUG

Seltorexant Low Dose

In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.

Trial Locations (1)

84124

PRAHS, Salt Lake City

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03682380 - A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants | Biotech Hunter | Biotech Hunter